Prime Therapeutics gives us a peek at its drug trend, via a press release. Maybe a full report will follow. (Prime Release) Prime is owned by a number of Blue Cross Blue Shield plans and they represent most of its customer base. It is currently probably the fourth largest PBM by number of people served, almost 20 million, and has a very extensive commercial business. It says it had a 2.5% increase in drug spending in 2016 (unclear if this is on a per capita basis). Specialty drug spending rose 13.7%, while traditional drug trend was a negative 1.7%. The company claims its various management tools saved clients $2.2 billion. Use of generics rose from an already high 83.1% in 2015 to 84.7% in 2016. Prime also highlighted growing use of preferred pharmacies and continued emphasis on certain diseases and drug categories. Diabetes and biologic anti-inflammatory drugs were highlighted as a major source of greater spending. Diabetes drugs account for 13% of all medication spending, and rose 18% on the back of a 10% increase in price and 6% increase in utilization. A care management program used by Prime was said to have reduced the trend to 7.5%. Anti-inflammatory drugs used for arthritis and other diseases accounted for 10% of all drug spending and 40% of specialty drug expenses in 2016. Prime noted its efforts to manage specialty drug spend across the medical and pharmacy benefits, which can be important as many infused and other specialty drugs end up being paid for outside of pharmacy benefits.
✅ Subscribe via Email
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at [email protected].
Healthy Skeptic Podcast
This is an outstanding report on total global drug spending and trends, with projections out to 2025. It helps you understand this important area of health care, which does much...
June 1, 2021
MedPAC 2019 Report to Congress
June 18, 2019
Two health care firms owned by private equity firms are merging in a transaction supposedly valued at $3 billion. HealthComp administers self-funded plans for employers and other groups and Virgin...
September 27, 2023
NextGen, an electronic medical records firm, is being put out of its public company misery, as a PE firm will pay $1.6 billion for the one-time high-flier.
September 7, 2023
A number of companies which attracted large financing rounds during the epidemic have imploded when reality set in. The latest is Cano Health, which is a little surprising since it...
August 15, 2023
Access ACO Care Management Chronic Disease Comparative Effectiveness Consumer Directed Health Consumers Devices Disease Management Drugs EHRs Elder Care End-of-Life Care FDA Financings Genomics Government Health Care Costs Health Care Quality Health Care Reform Health Insurance Health Insurance Exchange HIT HomeCare Hospital Hospital Readmissions Legislation M&A Malpractice Meaningful Use Medicaid Medical Care Medicare Medicare Advantage Mobile Pay For Performance Pharmaceutical Physicians Providers Regulation Repealing Reform Telehealth Telemedicine Wellness and Prevention Workplace